Existence of Quantum Pharmacology in Sartans: Evidence in Isolated Rabbit Iliac Arteries
Authors:
- Laura Kate GadanecLGLaura Kate Gadanec
- Jordan SwiderskiJSJordan Swiderski
- Vasso ApostolopoulosVasso Apostolopoulos
- Kostantinos KelaidonisKKKostantinos Kelaidonis
- Veroniki P. VidaliVVVeroniki P. Vidali
- Aleksander CankoACAleksander Canko
- Graham J. MooreGMGraham J. Moore
- John M. MatsoukasJohn M. Matsoukas
- Anthony ZulliAZAnthony Zulli
Open Access
- 16 December 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (24) , 17559
Abstract
Quantum pharmacology introduces theoretical models to describe the possibility of ultra-high dilutions to produce biological effects, which may help to explain the placebo effect observed in hypertensive clinical trials. To determine this within physiology and to evaluate novel ARBs, we tested the ability of known angiotensin II receptor blockers (ARBs) (candesartan and telmisartan) used to treat hypertension and other cardiovascular diseases, as well as novel ARBs (benzimidazole-N-biphenyl tetrazole (ACC519T), benzimidazole-bis-N,N′-biphenyl tetrazole (ACC519T(2)) and 4-butyl-N,N0-bis[[20-2Htetrazol-5-yl)biphenyl-4-yl]methyl)imidazolium bromide (BV6(K+)2), and nirmatrelvir (the active ingredient in Paxlovid) to modulate vascular contraction in iliac rings from healthy male New Zealand White rabbits in responses to various vasopressors (angiotensin A, angiotensin II and phenylephrine). Additionally, the hemodynamic effect of ACC519T and telmisartan on mean arterial pressure in conscious rabbits was determined, while the ex vivo ability of BV6(K+)2 to activate angiotensin-converting enzyme-2 (ACE2) was also investigated. We show that commercially available and novel ARBs can modulate contraction responses at ultra-high dilutions to different vasopressors. ACC519T produced a dose-dependent reduction in rabbit mean arterial pressure while BV6(K+)2 significantly increased ACE2 metabolism. The ability of ARBs to inhibit contraction responses even at ultra-low concentrations provides evidence of the existence of quantum pharmacology. Furthermore, the ability of ACC519T and BV6(K+)2 to modulate blood pressure and ACE2 activity, respectively, indicates their therapeutic potential against hypertension.Keywords
This publication has 99 references indexed in Scilit:
- Cardiovascular effects of angiotensin A: A novel peptide of the renin–angiotensin systemJournal of the Renin-Angiotensin-Aldosterone System, 2013
- Emergence of the Coherent Structure of Liquid WaterWater, 2012
- Magnetically sensitive light-induced reactions in cryptochrome are consistent with its proposed role as a magnetoreceptorProceedings of the National Academy of Sciences, 2012
- Nonlinear changes in the activity of the oxygen-dependent demethylase system in Rhodococcus erythropolis cells in the presence of low and very low doses of formaldehydeNonlinear Biomedical Physics, 2011
- Angiotensin II receptors and drug discovery in cardiovascular diseaseDrug Discovery Today, 2011
- Postconditioning Hormesis Put in Perspective: An Overview of Experimental and Clinical StudiesDose-Response, 2010
- Small-angle scattering and the structure of ambient liquid waterProceedings of the National Academy of Sciences, 2010
- Biological, clinical, and ethical advances of placebo effectsThe Lancet, 2010
- Differential Bonding Interactions of Inverse Agonists of Angiotensin II Type 1 Receptor in Stabilizing the Inactive StateMolecular Endocrinology, 2008
- Angiotensin receptors in resting smooth muscle are the low affinity sites observed in binding studiesLife Sciences, 1987